AZD 4916
Alternative Names: AZD-4916Latest Information Update: 06 Jul 2025
At a glance
- Originator AstraZeneca
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 12 May 2025 Preclinical trials in Unspecified in United Kingdom (PO)
- 30 Apr 2025 AstraZeneca plans phase-I safety and pharmacokinetics trial (In volunteers) in United Kingdom (PO) in June 2025 (NCT06951880)